ADAP Adaptimmune Therapeutics PLC
Price (delayed)
$0.25
Market cap
$64.44M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.3
Enterprise value
$45.44M
Adaptimmune is a clinical-stage biopharmaceutical company focused on the development of novel cancer immunotherapy products for people with cancer. The Company's unique SPEAR (Specific Peptide Enhanced Affinity Receptor) T-cell platform
Highlights
Adaptimmune Therapeutics's gross profit has surged by 195% YoY
The company's revenue has surged by 195% YoY
Adaptimmune Therapeutics's EPS has plunged by 150% from the previous quarter but it has increased by 44% YoY
Adaptimmune Therapeutics's net income has shrunk by 59% QoQ but it has increased by 38% YoY
The debt has surged by 194% year-on-year
Adaptimmune Therapeutics's equity has plunged by 85% from the previous quarter and by 70% YoY
Key stats
What are the main financial stats of ADAP
Market
Valuations
Earnings
Shares outstanding
257.75M
Market cap
$64.44M
Enterprise value
$45.44M
Price to earnings (P/E)
N/A
Price to book (P/B)
5.41
Price to sales (P/S)
0.36
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.26
Revenue
$178.03M
Gross profit
$177.96M
Operating income
-$68.76M
Net income
-$70.81M
EBIT
-$63.89M
EBITDA
-$52.67M
Free cash flow
-$74.09M
Per share
Balance sheet
Liquidity
EPS
-$0.3
EPS diluted
-$0.3
Free cash flow per share
-$0.29
Book value per share
$0.05
Revenue per share
$0.7
TBVPS
$0.96
Total assets
$245.96M
Total liabilities
$234.11M
Debt
$74.21M
Equity
$11.85M
Working capital
$123.64M
Debt to equity
6.26
Current ratio
2.92
Quick ratio
2.4
Net debt/EBITDA
0.36
Margins
Efficiency
Dividend
EBITDA margin
-29.6%
Gross margin
100%
Net margin
-39.8%
Operating margin
-38.6%
Return on assets
-24.8%
Return on equity
-133.3%
Return on invested capital
-50.5%
Return on capital employed
-35.2%
Return on sales
-35.9%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ADAP stock price
How has the Adaptimmune Therapeutics stock price performed over time
Intraday
26.9%
1 week
0%
1 month
-53.7%
1 year
-82.99%
YTD
-53.59%
QTD
26.9%
Financial performance
How have Adaptimmune Therapeutics's revenue and profit performed over time
Revenue
$178.03M
Gross profit
$177.96M
Operating income
-$68.76M
Net income
-$70.81M
Gross margin
100%
Net margin
-39.8%
Adaptimmune Therapeutics's gross profit has surged by 195% YoY
The company's revenue has surged by 195% YoY
ADAP's operating margin has soared by 83% YoY but it is down by 50% QoQ
The net margin has surged by 79% year-on-year but it has dropped by 57% since the previous quarter
Growth
What is Adaptimmune Therapeutics's growth rate over time
Valuation
What is Adaptimmune Therapeutics stock price valuation
P/E
N/A
P/B
5.41
P/S
0.36
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.26
Adaptimmune Therapeutics's EPS has plunged by 150% from the previous quarter but it has increased by 44% YoY
Adaptimmune Therapeutics's equity has plunged by 85% from the previous quarter and by 70% YoY
ADAP's price to book (P/B) is 49% lower than its last 4 quarters average of 8.3 but 12% higher than its 5-year quarterly average of 3.8
The company's revenue has surged by 195% YoY
The P/S is 100% below the 5-year quarterly average of 98.5 and 95% below the last 4 quarters average of 6.2
Efficiency
How efficient is Adaptimmune Therapeutics business performance
Adaptimmune Therapeutics's ROS has soared by 81% YoY but it has plunged by 51% from the previous quarter
The return on equity has dropped by 80% since the previous quarter
Adaptimmune Therapeutics's return on assets has shrunk by 64% QoQ but it has increased by 34% YoY
The company's return on invested capital rose by 35% YoY but it fell by 32% QoQ
Dividends
What is ADAP's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ADAP.
Financial health
How did Adaptimmune Therapeutics financials performed over time
ADAP's total assets is 5% greater than its total liabilities
ADAP's current ratio is down by 24% QoQ but it is up by 2.5% YoY
The company's quick ratio fell by 24% QoQ but it rose by 16% YoY
The debt has surged by 194% year-on-year
Adaptimmune Therapeutics's equity has plunged by 85% from the previous quarter and by 70% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.